S&P: Amgen unaffected

Standard & Poor's said ratings on Amgen Inc. (A+/negative/A-1) remain unchanged following the company's announcement about a $1.5 billion accelerated share repurchase program.

Amgen continues to maintain conservative financial policies, the agency said, with a net debt-to-EBITDA ratio of less than 1 times.

Amgen is facing some challenges to its Aranesp/Epogen franchise but S&P said it believes that sales should remain significant and that its two other main franchises remain strong.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.